Login to Your Account



‘Tivo’ off screen: Astellas ending Aveo VEGF deal after failure reruns

By Randy Osborne
Staff Writer

Friday, February 14, 2014
deals_and_ma.jpg

Steadily declining hopes for tivozanib, the tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF) receptors, hit bottom with Astellas Pharma Inc.’s decision to quit its deal with Aveo Oncology Inc., which brought $125 million up front in 2011 and the promise of more than $1 billion in potential milestone payments.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription